Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI vs. doctors: who picks the best day for IVF?

NCT ID NCT07515118

Knowledge-focused Sponsor: Fundacion Dexeus Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether an artificial intelligence program called STIMAI® can help choose the best day to give the final 'trigger' shot in IVF, compared to doctors making the decision alone. About 644 women undergoing ovarian stimulation for IVF will be randomly assigned to either AI-guided or doctor-led care. The main goal is to see if the number of mature eggs retrieved is similar between the two groups.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
STIMAI® artificial intelligence software
What this could lead to
If successful, this could show that AI can help doctors make better decisions about when to trigger ovulation, potentially improving IVF success rates and reducing the burden on patients.
What could go wrong
This is an early-stage trial comparing AI to standard care, so it may not show a clear benefit. The AI is only a decision-support tool, and final decisions rest with the doctor, limiting its direct impact.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 644 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2026

Expected to finish

Sep 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 42 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Undergoing COS for IVF with autologous oocytes, oocyte donation and elective fertility preservation with all monitoring USS (ultrasound scan) conducted at our centers. Exclusion Criteria: * Medically indicated fertility preservation * Inability to attend clinic visits for monitoring.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Artificial intelligence are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

infertility disorder ovarian hyperstimulation syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Artificial intelligence Infertility Ovarian stimulation

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    5 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Dexeus Mujer Reus

    NOT_YET_RECRUITING

    Reus, Tarragona, 43202, Spain

  • Dexeus Mujer Sabadell

    NOT_YET_RECRUITING

    Sabadell, Barcelona, Spain

  • Dexeus Mujer Sant Cugat

    NOT_YET_RECRUITING

    Sant Cugat del Vallès, Barcelona, 08195, Spain

  • Dexeus Mujer Tarragona

    NOT_YET_RECRUITING

    Tarragona, 43206, Spain

  • Hospital Universitario Quiron Dexeus

    RECRUITING

    Barcelona, 08028, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.